aap Implantate AG, a medical technology company listed in the Prime Standard segment of the Frankfurt Stock Exchange, earned sales revenue totaling EUR 5.8 million (previous year: EUR 8.4 million) in the first three months of the financial year 2010. Its EBITDA was EUR 0.2 million (previous year: EUR 0.8 million).

In the first quarter of 2010 the Group’s EBIT amounted to EUR -0.5 million (previous year: EUR 0.1 million). Group EBT was EUR -0.7 million (previous year: EUR -0.2 million). On a balance sheet total of EUR 61.1 million (Dec. 31, 2009: EUR 62.7 million) the equity ratio was 72 percent.

Disregarding project sales, the sales of the disposed Analytics business sold in December 2009, and other one-time effects, amounting to EUR 2.4 million, like-for-like previous year’s product sales totaled EUR 5.9 million. Therefore Q1 2010 sales were 2 percent down on the previous year.

Taking out the effects of the Analytics business and the effect of the project business, the adjusted key performance figures for the first quarter of 2009 are as follows:

*Q1/2009 adjusted for effects of Analytics segment and project business

The main focus of the corporate strategy in 2010 continues to be on customers, costs and cash. aap´s financial goal is to achieve a positive EBIT at product level by launching new and innovative products and by launching existing products in new markets, by expanding longstanding partnerships and by establishing new ones in 2010. Based on current forecasts and the present state of various negotiations the Management Board anticipates double-digit H1 sales growth at product level.

aap Implantate AG’s Q1 2010 results in full are available to download at www.aap.de.